

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61F 2/28, A61L 25/00, 27/00	A1	(11) International Publication Number: WO 99/18894 (43) International Publication Date: 22 April 1999 (22.04.99)
<p>(21) International Application Number: PCT/US98/21576</p> <p>(22) International Filing Date: 13 October 1998 (13.10.98)</p> <p>(30) Priority Data: 08/950,256 14 October 1997 (14.10.97) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/950,256 (CIP) Filed on 14 October 1997 (14.10.97)</p> <p>(71) Applicant (for all designated States except US): PARALLAX MEDICAL, INC. [US/US]; Suite B, 453 Ravendale Drive, Mountain View, CA 94043 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): PREISSMAN, Howard [US/US]; 2140 Jonathon Avenue, San Jose, CA 95125 (US).</p> <p>(74) Agents: CANNON, Alan, W. et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, OW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: **ENHANCED VISIBILITY MATERIALS FOR IMPLANTATION IN HARD TISSUE**

(57) Abstract

An enhanced visibility composition for implantation from a remote source, so that the composition can be readily observed under fluoroscopy or other imaging techniques. The compositions include a biocompatible matrix, such as a hard tissue implant material for example, and radiopaque particles mixed in the matrix. The radiopaque particles have a particle size between about 120 μ and 2200 μ , more preferably about 350 μ and 2200 μ , even more preferably between about 450 μ and 1600 μ , and most preferably between about 570 μ and 1150 μ . Preferably the hard tissue implant and the radiopaque particles are formed or prepared in a slurry. Optionally, the enhanced visibility composition may further include additional radiopaque particles or contrast particles mixed in with the composition, which have a particle size between about 120 μ and 350 μ , preferably between about 120 μ and 250 μ .

In Re: Kieran P.J. Murphy, M.D.
Serial No.: 09/594,685
Date Filed: June 16, 2001

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ENHANCED VISIBILITY MATERIALS FOR IMPLANTATION IN HARD TISSUE

TECHNICAL FIELD

5 The present invention relates to compositions for use as tissue implants, preferably hard tissue implants. More particularly, the present invention is directed to compositions which are more easily viewed by imaging techniques, during the implantation thereof, than compositions that are presently known and used. A particularly advantageous use of the present invention is for percutaneous injection of hard tissue implant materials, although the invention is not to be so limited.

BACKGROUND ART

10 Polymethylmethacrylate (PMMA) has been used in anterior and posterior stabilization of the spine for metastatic disease, as described by Sundaresan et al., "Treatment of neoplastic epidural cord compression by vertebral body resection and stabilization." *J Neurosurg* 1985;63:676-684; Harrington, "Anterior decompression and stabilization of the spine as a treatment for vertebral collapse and spinal cord compression from metastatic malignancy." *Clinical Orthopaedics and Related Research* 1988;233:177-197; and Cybulski, "Methods of surgical stabilization for metastatic disease of the spine." *Neurosurgery* 1989;25:240-252.

20 Deramond et al., "Percutaneous vertebroplasty with methyl-methacrylate: technique, method, results [abstract]." *Radiology* 1990;117 (suppl):352; among others, have described the percutaneous injection of PMMA into vertebral compression fractures by the transpedicular or paravertebral approach under CT and/or fluoroscopic guidance. Percutaneous vertebroplasty is desirable from the standpoint that it is minimally invasive, compared to the alternative of surgically exposing the hard tissue site to be supplemented with PMMA or other filler.

25 The general procedure for performing percutaneous vertebroplasty includes the percutaneous injection of PMMA or other bone implant material into the damaged or fractured bone tissue of a vertebra. During injection of the bone implant material, fluoroscopic imaging or another imaging technique is used to track the path that the bone

implant material takes as well as its final position upon implantation. Contrast agents such as barium sulfate powder are often used to aid the visibility of the bone implant material by imaging. However, the barium sulfate powders and other contrast agents presently used are generally very fine. This type of contrast agent is fairly effective once a given mass of the mixture of it with the bone implant material has accumulated at an implant site. However, for purposes of tracking the flow and leading edge surfaces of a bone implant material during injection, or for viewing small volumes of the implant material, the contrast agents presently used are inadequate.

This inadequacy becomes especially important during injection of liquid or flowable bone implant materials, as is the case with percutaneous vertebroplasty, since viewing of the path taken by the implant material is very important. That is because the bone implant material may take a path where it begins to enter the venous system, where it is not only unwanted, but where it could have very damaging effects. Thus, an improvement in the visibility of bone implant materials during injection is needed.

The use of radiographic contrast agents in a three dimensional, solid conglomerate of polymer particles which is used as a starting material for the preparation of bone cement is disclosed by Draenert in U.S. Patent No. 5,574,075. The agents may be particulate, having a size range of between 5 and 300 μm . Draenert makes the three-dimensional conglomerate of polymeric particles, with the idea of converting the powder phase of the precursors of a PMMA bone cement mixture into a solid phase, similar to cube sugar.

Cooke et al., in U.S. Patent No. 5,476,880, discloses the incorporation of sized, radiopaque particles into a PMMA bone composition that is additionally reinforced with previously sized reinforcing fibers. The preferred radiopaque agent is zirconium dioxide, which may be present at a level between 1-15% by weight of the powder. Barium sulfate may also be used. The radiopaque powder preferably has a diameter of about 1 μ .

Accordingly, there exists a need for a more visible composition to enable the tracking of the path of implantation taken by an implantable bone composition, particularly flowable or liquid compositions which are implanted from a remote site, by injection or other means.

DISCLOSURE OF THE INVENTION

An enhanced visibility composition for implantation into hard tissue is disclosed as including a hard tissue implant material and radiopaque particles mixed in the hard tissue implant material. The radiopaque particles have a particle size between about 120 μ and 2200 μ , more preferably between about 350 μ and 2000 μ , even more preferably between about 450 μ and 1600 μ , and most preferably between about 570 μ and 1150 μ . Other acceptable particle size ranges are disclosed to include between about 350 μ and 2200 μ , between about 450 μ and 2200 μ , between about 570 μ and 2200 μ , between about 350 μ and 1600 μ , between about 350 μ and 1150 μ , and between about 450 μ and 1150 μ .

Preferably the hard tissue implant and the radiopaque particles, according to the present invention, are formed or prepared in a slurry for implantation. The hard tissue implant material preferably includes polymethyl methacrylate. Alternative hard tissue implant materials that may be mixed with the radiopaque particles include hydroxyapatite, various formulations of biocompatible calcium phosphates, biocompatible calcium sulfates, demineralized and/or mineralized bone particles, polymer based implants including polyglycolic acid and or polylactic acid compounds, collagen and/or collagen derivative preparations alone or in combination with other biomaterials, chitin and/or chitosan preparations, bioglasses including oxides of silicon, sodium, calcium and phosphorous and combinations thereof, and other known materials which are acceptable for use as hard tissue implant materials including osteogenic and osteoinductive compositions, and combinations thereof.

The radiopaque particles may include barium sulfate, tungsten, tantalum, zirconium, platinum, gold, silver, stainless steel, titanium, alloys thereof, combinations thereof, or other equivalent materials for use as radiographic agents in hard tissue implant materials that can be formed as particles.

Optionally, the enhanced visibility composition according to the present invention may further include additional radiopaque particles or contrast particles mixed in with the composition. The additional radiographic or contrast particles may have a particle size between about 120 μ and 350 μ , preferably between about 120 μ and 250 μ .

The additional radiopaque or contrast particles may include barium sulfate, bismuth subcarbonate, bismuth sulfate, powdered tungsten, powdered tantalum, zirconium, combinations thereof, or other equivalent materials for use as radiographic agents in hard tissue implant materials that can be formed as particles. Additionally, liquid or soluble contrast agents may be used, e.g., Metrizamide, disclosed in U.S. Patent No. 3,701,771 or Iopromide, disclosed in U.S. Patent No. 4,364,921. Both U.S. Patent No. 3,701,771 and 4,364,921 are hereby incorporated by reference herein in their entireties. The composition of the additional radiopaque or contrast particles may, but need not be the same as the composition of the radiographic particles.

Further disclosed is a composition for percutaneous vertebroplasty comprising a slurry of biocompatible implant material and radiopaque markers having a particle size of between about 120 μ and 2200 μ . All of the size ranges given above for the radiographic particles are suitable for the radiopaque markers. Preferably, the radiopaque markers have a particle size between about 570 μ and 1150 μ . The biocompatible implant material of the slurry preferably includes polymethyl methacrylate. Alternative implant materials include hydroxyapatites, calcium phosphates, demineralized bone particles, and other known bone implant materials, including osteogenic and osteoinductive compositions.

The composition for percutaneous vertebroplasty may optionally include contrast particles having a particle size between about 120 μ and 350 μ .

Additionally, an injectable composition is described, which includes a biocompatible matrix which may include soft tissue implants as well as hard tissue implants, and radiopaque particles mixed within the biocompatible matrix. The radiopaque particles have a particle size between about 350 μ and 2200 μ , more preferably between about 450 μ and 1600 μ , and most preferably between about 570 μ and 1150 μ .

The biocompatible matrix and radiopaque particles preferably form a slurry. Preferably, the slurry comprises an injectable composition for implantation in hard tissue. Further, contrast particles having a particle size between about 120 μ and 350 μ may be included in the injectable composition.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a sectional view of an injection of a prior art bone implant material into a damaged vertebra:

Fig. 2 is a sectional view of an injection of a bone implant material according to the present invention, into a damaged vertebra:

Fig. 3 is a schematic representation of a hard tissue implant matrix, with radiopaque markers mixed therein according to the present invention; and

Fig. 4 is a schematic representation of a hard tissue implant matrix, with radiopaque markers and a small particle contrast agent mixed therein according to the present invention.

BEST MODE FOR CARRYING OUT THE INVENTION

The percutaneous injection of polymethylmethacrylate (PMMA) is a recent technique of treating pain associated with acute vertebral body compression fractures that is showing a great deal of promise as an effective treatment method. The PMMA is in a slurry state when it is percutaneously injected. The slurry is prepared just prior to the injection by mixing a powder component, e.g., methyl methacrylate polymer, with a liquid component, e.g., methylmethacrylate monomer. Additional components such as copolymers (e.g., styrene,), accelerators (e.g., N,N-dimethyl paratoluidene), initiators (e.g., benzoyl peroxide), stabilizers (e.g., hydroquinone) and/or antibiotics (e.g., Tobramycin) may be included in the slurry. Note that the above are only examples of the many additives that are currently used in PMMA compositions for implantation, and the other known additives are acceptable for the purposes of the present invention.

Contrast agents such as barium sulfate and zirconium dioxide have also been added to the PMMA mixture. Contrast agents are typically in the form of fine powders having a very fine particle size on the order of a few microns. Upon injection of the PMMA into the vertebral body using, for example, a long 11 gauge cannula, the opacification of the PMMA increases, as viewed by an imaging technique such as fluoroscopy, or X-ray, CT, MRI or other accepted modality of medical imaging, as the volume of the PMMA accumulates at the implantation site.

As indicated in Figure 1, however, small volumes of the injected PMMA 20, when viewed under fluoroscopy, or other imaging technique, are difficult to discern. More specifically, it is often difficult to visually distinguish between the PMMA 20 and the bony landmarks 21 in the visual field, especially when the PMMA 20 has just begun to flow and the volume delivered is thus very low. In small volumes, the PMMA 20 appears as a very faint grayish hue when viewed under fluoroscopy. The gray hue becomes darker as more PMMA 20 is injected and the volume begins to accumulate at the implant site. However, better visualization of the implant material is required to track the flow of the implant material so as to prevent an inadvertent injection into a vein, which could transport the material to the lungs of the patient, occlude the vein, or cause other various forms of damage to the patient.

Figure 2 indicates the enhanced visibility of an implant material 1 which is percutaneously injected into a vertebra 6, using an 11 gauge cannula 5, for example. In the example shown in Figure 2, the composition 1 is exactly the same as the composition 20 shown in Figure 2, except for an addition of larger particle radiopaque tracers 2. The radiopaque tracers are particles having a particle size between about 120μ and 2200μ . The particle size range of the tracers used may vary and include ranges such as: between about 350μ and 2200μ ; between about 350μ and 2000μ ; between about 570μ and 2200μ ; between about 350μ and 1600μ ; between about 350μ and 1150μ ; between about 450μ and 1150μ ; and between about 450μ and 1600μ . A preferred particle size range for the tracers is between about 570μ and 1150μ .

As illustrated in Figure 2, the radiopaque tracers can be clearly and individually identified under fluoroscopy having a magnification of 4X, or other imaging technique as described above, as they exit the cannula 5, even during the initial flow of the implant material 1 from the cannula 5. Thus, an accumulation of the implant material is not required before accurate visual tracking can begin. Importantly, the flow of the material of the present invention can be easily viewed. Also the shape of the tracers 2 is readily identifiable and distinguishable from the bony landmarks 21 of the implant site.

The addition of radiopaque tracers 2 to the composition 1, increases the visibility of the composition without substantially effecting the viscosity of the composition. The

addition of the tracers 2 creates a quasi-homogenous slurry in which the tracers appear as dark gray spots under fluoroscopy. The tracer particles are individually viewable under medical fluoroscopy at a magnification of 4X or greater.

5 The radiopaque tracers 2 may be added to the composition with or without a conventional contrast agent. Alternatively, the addition of significantly more particles having a particle size of about 120 μ to 350 μ , more preferably about 120 μ to 250 μ to the composition 20, in addition to a significantly lesser concentration of particles having a large size range of about 350 μ to 2200 μ , more preferably about 450 μ and 1600 μ , and most preferably between about 570 μ and 1150 μ . The larger concentration of small particles acts
10 to enhance viewing of the accumulated mass of the implant, while the larger particles perform the "tracing" function, allowing the flow of the implant to be viewed under fluoroscopy or other medical imaging device.

The addition of tracer particles to an implantable composition enhances the visibility of the composition, particularly enabling the viewing of the flow, without
15 significantly increasing the viscosity or setting times of the composition. Alternatively, if one were to merely increase the concentration of the convention fine powder contrast agent, to attempt to enhance the visibility of the composition, significantly increases in the viscosity of the composition ensue, and the polymerization times may be adversely effected. Of course, an increase in viscosity adversely effects the ability to effectively
20 inject a composition. Not only does it become more difficult to pass the composition through whatever injection apparatus is to be used, but the composition also is less able to permeate all of the porosities, defects, or other tortuous pathways which are intended to be filled by the implantable composition, since it is simply less flowable and less dispersible.

25 Thus, the simple addition of more fine powder radiopaque contrast agent is not an acceptable solution to making a more visible implantable composition. This makes the slurry too viscous for adequate perfusion throughout the vertebral body or other hard tissue site and additionally requires larger injection forces, thereby increasing the risk of accidents, such as breaking the delivery cannula during injection.

However, the addition of tracer particles having size ranges as indicated above, in small concentrations, enhances the visualization of the composition, as illustrated in Figure 2, without increasing the viscosity or the pressure requirements to inject the composition. Nor are the polymerization times of the resultant composition substantially shortened or otherwise adversely effected.

As illustrated in Figure 3, the radiopaque tracers 2 according to the present invention can also be effectively used in a composition 1' without the use of a contrast agent. A viscosity adjustment of the composition, in the case of PMMA can be made by simply increasing the powder phase of the polymer to make up for any decrease in viscosity that might occur by leaving out the contrast agent.

The radiopaque particles may be formed from barium sulfate, zirconium dioxide, tantalum, tungsten, platinum, gold, silver, stainless steel, titanium, alloys thereof, combinations thereof, or other known materials used as contrast agents for implants. Additionally, combinations of the particles may be added to the mixture. When a contrast agent is also included in the mixture, the contrast agent may be made from the same materials as the tracers, or from a different material or mixture of material particles. The same materials disclosed above as being acceptable for use as tracer particles are acceptable for use as contrast agents. Similarly, when two ranges of tracer particle sizes are used, as illustrated in Figure 4, the smaller size group 4 may be made from the same materials as the larger size group 2, or from a different material or mixture of material particles. If used, the smaller size particles should be formed from particles having a particle size between about 120 μ and 350 μ , preferably between about 120 μ and 250 μ .

The matrix 3 or implant material into which the radiopaque markers 2 may be mixed, is not limited to PMMA, but may also be added to hydroxyapatite mixtures, calcium phosphate mixtures, calcium sulfate mixtures, demineralized or mineralized bone particle compositions, polymer based implants including polyglycolic acid and or polylactic acid compounds, collagen and/or collagen derivative preparations alone or in combination with other biomaterials, chitin and/or chitosan preparations, bioglasses including oxides of silicon, sodium, calcium and phosphorous and combinations thereof, and other known materials which are acceptable for use as hard tissue implant materials

including osteogenic and osteoinductive compositions, and combinations thereof, as well as other known hard tissue fillers and implant materials. Additionally, the tracers may be included in a matrix for soft tissue implantation, including materials such as silicon, collagens, gelatins, and various other soft tissue implant materials.

5 Although the present invention is preferably directed at remotely deliverable hard tissue implant materials, and particularly slurries, it is not to be so limited, but may be used in other compositions where an enhanced visualization of the material is desired. For example, the tracers could be used in a more viscous composition of PMMA to be implanted manually at the implantation site, e.g. the anchoring of an acetabular cup or knee
10 prosthesis.

EXAMPLES

Example 1 - A slurry of PMMA is prepared from about 10 g of a powder phase which is 15% w/w polymethylmethacrylate, 74% w/w methacrylate-styrene copolymer,
15 10% w/w commercially available barium sulfate powder (e.g., E-Z-EM, Westbury, NY), and 1% w/w tracer particles made of barium sulfate particles having a particle size within the range of between about 570 and 1150 μ . To the powder phase is added about 6-9 cc of a liquid phase made up of about 97.4% v/v methacrylate monomer; about 2.6% v/v N,N-dimethyl-p-toluidene; and 75 \pm 15 ppm hydroquinone. The slurry is thoroughly mixed until
20 a cake glaze like consistency is reached, at which time the composition is ready for implantation.

Example 2 - A 10cc volume slurry of PMMA is prepared from a powder phase which is 15% w/w polymethylmethacrylate, 75% w/w methacrylate-styrene copolymer, and 10% w/w tracer particles made of a mixture of barium sulfate particles and tungsten
25 particles, each having a particle size within the range of between about 570 and 1150 μ .

CLAIMS

What is claimed is:

1. An enhanced visibility composition for implantation into hard tissue comprising:

5 a hard tissue implant material; and
 radiopaque particles mixed in said hard tissue implant material, said radiopaque particles having a particle size between about 350 μ and 2200 μ .

2. The enhanced visibility composition of claim 1, wherein said hard tissue implant and said radiopaque particles are formed in a slurry.

10 3. The enhanced visibility composition of claim 1, wherein said hard tissue implant material comprises polymethyl methacrylate.

4. The enhanced visibility composition of claim 1, wherein said hard tissue implant material comprises hydroxyapatite.

15 5. The enhanced visibility composition of claim 1, wherein said hard tissue implant material comprises calcium phosphates.

6. The enhanced visibility composition of claim 1, wherein said hard tissue implant material comprises calcium sulfates.

20 7. The enhanced visibility composition of claim 1, wherein said hard tissue implant material comprises at least one of the materials selected from the group consisting of demineralized bone particles and mineralized bone particles.

8. The enhanced visibility composition of claim 1, wherein said hard tissue implant material comprises at least one of the materials selected from the group consisting of polyglycolic acid compounds and polylactic acid compounds

25 9. The enhanced visibility composition of claim 1, wherein said hard tissue implant material comprises at least one of the materials selected from the group consisting of collagen and collagen derivatives.

10. The enhanced visibility composition of claim 1, wherein said hard tissue implant material comprises at least one of the materials selected from the group consisting of chitin and chitosan.

11. The enhanced visibility composition of claim 1, wherein said hard tissue implant material comprises at least one of the materials selected from the group consisting of bioglasses including oxides of silicon, sodium, calcium and phosphorous and combinations thereof.

5 12. The enhanced visibility composition of claim 1, wherein said radiopaque particles have a particle size between about 450 μ and 2200 μ .

13. The enhanced visibility composition of claim 1, wherein said radiopaque particles have a particle size between about 570 μ and 2200 μ .

10 14. The enhanced visibility composition of claim 1, wherein said radiopaque particles have a particle size between about 350 μ and 1600 μ .

15. The enhanced visibility composition of claim 9, wherein said radiopaque particles have a particle size between about 350 μ and 1150 μ .

16. The enhanced visibility composition of claim 15, wherein said radiopaque particles have a particle size between about 450 μ and 1150 μ .

15 17. The enhanced visibility composition of claim 1, wherein said radiopaque particles have a particle size between about 570 μ and 1150 μ .

18. The enhanced visibility composition of claim 14, wherein said radiopaque particles have a particle size between about 450 μ and 1600 μ .

20 19. The enhanced visibility composition of claim 1, further comprising:
additional radiopaque particles mixed in said hard tissue implant material, said additional radiopaque particles having a particle size between about 120 μ and 350 μ .

20. The enhanced visibility composition of claim 1, wherein said additional radiopaque particles have a particle size between about 120 μ and 250 μ .

25 21. The enhanced visibility composition of claim 1, wherein said radiopaque particles comprise barium sulfate.

22. The enhanced visibility composition of claim 1, wherein said radiopaque particles comprise tungsten.

23. The enhanced visibility composition of claim 1, wherein said radiopaque particles comprise tantalum.

24. The enhanced visibility composition of claim 19, wherein said additional radiopaque particles comprise barium sulfate.

25. The enhanced visibility composition of claim 19, wherein said additional radiopaque particles comprise tungsten.

5 26. The enhanced visibility composition of claim 19, wherein said additional radiopaque particles comprise tantalum.

27. A composition for percutaneous vertebroplasty comprising a slurry of biocompatible implant material and radiopaque markers having a particle size of between about 120 μ and 2200 μ .

10 28. The composition of claim 27, wherein said biocompatible implant material comprises polymethyl methacrylate.

29. The composition of claim 27 wherein said markers have a particle size between about 350 μ and 2000 μ .

15 30. The composition of claim 29 wherein said markers have a particle size between about 450 μ and 1600 μ .

31. The composition of claim 30, further comprising contrast particles, wherein said contrast particles have a particle size between about 120 μ and 350 μ .

32. The composition of claim 31 wherein said markers have a particle size between about 570 μ and 1150 μ .

20 33. An injectable composition comprising:
a biocompatible matrix; and
radiopaque particles mixed within said biocompatible matrix, said radiopaque particles having a particle size between about 120 μ and 2200 μ .

25 34. The injectable composition of claim 33, wherein said biocompatible matrix and said radiopaque particles form a slurry.

35. The injectable composition of claim 33, wherein the mixture of said biocompatible matrix and said radiopaque particles forms a hard tissue implant material.

36. The injectable composition of claim 33, wherein said radiopaque particles have a particle size between about 350 μ and 2200 μ .

30 37. The injectable composition of claim 36, further comprising:

contrast particles having a particle size between about 120 μ and 350 μ .

38. The injectable composition of claim 36, wherein said radiopaque particles having a particle size between about 450 μ and 1600 μ .

5 39. The injectable composition of claim 38, wherein said radiopaque particles having a particle size between about 570 μ and 1150 μ .

40. An enhanced visibility composition comprising:

a flowable matrix; and

radiopaque particles in said flowable matrix, said radiopaque particles being of a size and concentration so as to be individually visible under medical fluoroscopy.

10 41. The enhanced visibility composition of claim 40, wherein said radiopaque particles have a size between about 120 μ and 2200 μ .

1/2




Fig. 1
(PRIOR ART)




Fig. 2

2/2




Fig. 3




Fig. 4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/21576

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61F2/28 A61L25/00 A61L27/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 04924 A (DRAENERT KLAUS) 2 April 1992 see page 5, line 29 - page 6, line 4 ---	27, 28, 33-35, 40, 41
X	US 5 574 075 A (DRAENERT KLAUS) 12 November 1996 cited in the application	27, 28, 33-35; 40, 41
Y	see column 2, line 45 - line 57 --- -/--	1-3, 12-18, 21-23, 29, 30, 32, 36, 38, 39

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

18 February 1999

Date of mailing of the international search report

26/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Heck, G

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/US 98/21576

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	US 5 676 146 A (SCARBOROUGH NELSON L) 14 October 1997	1-3, 12-18, 21-23, 29,30, 32,36, 38,39
	see column 2, line 12 - line 30 ---	
A	WO 97 04657 A (EVANS SCOTT ;GREFF RICHARD J (US); JONES MICHAEL L (US); MICRO THE) 13 February 1997 see claims 1,4 -----	1,21-26

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/21576

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9204924	A	02-04-1992	DE 4029714 A EP 0548193 A JP 6500718 T	26-03-1992 30-06-1993 27-01-1994
US 5574075	A	12-11-1996	DE 4033343 A AU 8732791 A WO 9206717 A EP 0555261 A JP 6502086 T	23-04-1992 20-05-1992 30-04-1992 18-08-1993 10-03-1994
US 5676146	A	14-10-1997	AU 4270397 A WO 9810712 A	02-04-1998 19-03-1998
WO 9704657	A	13-02-1997	US 5667767 A US 5580568 A AU 6604296 A AU 6604396 A CA 2215272 A CA 2215356 A CN 1192654 A EP 0841854 A EP 0847240 A WO 9704656 A US 5851508 A AU 6639796 A CA 2215311 A EP 0843560 A WO 9704813 A	16-09-1997 03-12-1996 26-02-1997 26-02-1997 13-02-1997 13-02-1997 09-09-1998 20-05-1998 17-06-1998 13-02-1997 22-12-1998 26-02-1997 13-02-1997 27-05-1998 13-02-1997